View source for Template:Androgen/anabolic steroid dosages for breast cancer

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Androgen/anabolic steroid dosages for breast cancer|mini=y}} <noinclude>[[Androgen]]</noinclude><includeonly>Androgen</includeonly>/<noinclude>[[anabolic steroid]]</noinclude><includeonly>anabolic steroid</includeonly> dosages for <noinclude>[[breast cancer]]</noinclude><includeonly>breast cancer</includeonly>
|-
! Route !! Medication !! Form !! Dosage <noinclude>!! Refs</noinclude>
|-
| rowspan="4" | [[Oral administration|Oral]] || {{No selflink|Methyltestosterone}} || Tablet || 30–200 mg/day <noinclude> || <ref name="Lupulescu1990" /><ref name="Dao1975" /><ref name="Android-Label">{{cite web | title = Android® C-III | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/083976s031lbl.pdf | work = Valeant Pharmaceuticals North America | publisher = U.S. Food and Drug Administration }}</ref><ref name="Ebadi2007">{{cite book| vauthors = Ebadi M |title=Desk Reference of Clinical Pharmacology|url=https://books.google.com/books?id=ihxyHbnj3qYC&pg=PA434|date=31 October 2007|publisher=CRC Press|isbn=978-1-4200-4744-8|pages=434–}}</ref></noinclude>
|-
| {{No selflink|Fluoxymesterone}} || Tablet || 10–40 mg 3x/day <noinclude> || <ref name="Lupulescu1990">{{cite book| vauthors = Lupulescu A |chapter=Hormones and Hormonotherapy|title=Hormones and Vitamins in Cancer Treatment|chapter-url=https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57|date=24 October 1990|publisher=CRC Press|isbn=978-0-8493-5973-6|pages=33–90}}</ref><ref name="Perry2008">{{cite book| vauthors = Perry MC |title=The Chemotherapy Source Book|url=https://books.google.com/books?id=CDADMzS0TKUC&pg=PA369|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7328-7|pages=369–}}</ref><ref name="Martz2013">{{cite book| vauthors = Martz G |title=Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms|url=https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA39|date=13 March 2013|publisher=Springer-Verlag|isbn=978-3-642-86282-3|pages=39–}}</ref><ref name="Brotherton1976" /></noinclude>
|-
| {{No selflink|Calusterone}} || Tablet || 40–80 mg 4x/day <noinclude> || <ref name="Lupulescu1990" /><ref name="Brotherton1976" /></noinclude>
|-
|-
| {{No selflink|Normethandrone}} || Tablet || 40 mg/day <noinclude> || <ref name="Dao1975" /></noinclude>
|-
| [[Buccal administration|Buccal]] || {{No selflink|Methyltestosterone}} || Tablet || 25–100 mg/day <noinclude> || <ref name="Ebadi2007" /></noinclude>
|-
| rowspan="10" | [[Injection (medicine)|Injection]] ({{abbrlink|IM|intramuscular injection}} or {{abbrlink|SC|subcutaneous injection}}) || {{No selflink|Testosterone propionate}} || Oil solution || 50–100 mg 3x/week <noinclude> || <ref name="Lupulescu1990" /><ref name="Dao1975">{{cite book | vauthors = Dao TL | chapter = Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms | year = 1975 | pages = 170–192 | doi = 10.1007/978-3-642-65806-8_11 | editor1 = Alan C. Sartorelli | editor2 = David G. Johns | title = Antineoplastic and Immunosuppressive Agents | chapter-url = https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 | isbn = 978-3-642-65806-8}}</ref><ref name="AMA1960">{{cite journal | author = Council on Drugs | year = 1960 | title = Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients | journal = JAMA | volume = 172 | issue = 12 | pages = 1271–83 | doi = 10.1001/jama.1960.03020120049010}}</ref><ref name="Martz2013" /><ref name="Brotherton1976">{{cite book| vauthors = Brotherton J |title=Sex Hormone Pharmacology|url=https://books.google.com/books?id=zt5sAAAAMAAJ|year=1976|publisher=Academic Press|isbn=978-0-12-137250-7|pages=437}}</ref></noinclude>
|-
| {{No selflink|Testosterone enanthate}} || Oil solution || 200–400 mg 1x/2–4&nbsp;weeks <noinclude> || <ref name="Delatestryl-Label">{{cite web | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009165s031lbl.pdf | title = DELATESTRYL® CIII (Testosterone Enanthate Injection, USP) | publisher = U.S Food and Drug Administration }}</ref><ref name="AMA1983">{{cite book|author1=American Medical Association. Division of Drugs|author2=American Society for Clinical Pharmacology and Therapeutics|chapter=Androgens and Anabolic Steroids|pages=913–930|title=AMA Drug Evaluations|url=https://books.google.com/books?id=tsVKAQAAIAAJ|year=1983|publisher=American Medical Association|isbn=978-0-89970-160-8|quote=TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks.}}</ref></noinclude>
|-
| {{No selflink|Testosterone cypionate}} || Oil solution || 200–400 mg 1x/2–4&nbsp;weeks <noinclude> || <ref name="AMA1983" /><ref name="pmid14182428">{{cite journal | vauthors = Green RB, Sethi RS, Lindner HH | title = Treatment of advanced carcinoma of the breast: Progress in therapy during the past decade | journal = Am. J. Surg. | volume = 108 | pages = 107–21 | date = July 1964 | pmid = 14182428 | doi = 10.1016/0002-9610(64)90094-7 }}</ref></noinclude>
|-
| {{No selflink|Mixed testosterone esters}} || Oil solution || 250 mg 1x/week <noinclude> || <ref name="Martz2013" /></noinclude>
|-
| {{No selflink|Methandriol}} || Aqueous suspension || 100 mg 3x/week <noinclude> || <ref name="AMA1960" /><ref name="pmid14182428" /></noinclude>
|-
| {{No selflink|Androstanolone|Androstanolone ({{Abbr|DHT|dihydrotestosterone}})}} || Aqueous suspension || 300 mg 3x/week <noinclude> || <ref name="Dao1975" /><ref name="AMA1960" /><ref name="SegaloffHorwitt1955">{{cite journal | vauthors = Segaloff A, Horwitt BN, Carabasi RA, Murison PJ, Schlosser JV | title = Hormonal therapy in cancer of the breast. VIII. The effect of dihydrotestosterone (androstanolone) on clinical course and hormonal excretion | journal = Cancer | volume = 8 | issue = 1 | pages = 82–86 | year = 1955 | pmid = 13231036 | doi = 10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R | s2cid = 10089663 }}</ref><ref name="pmid14182428" /></noinclude>
|-
| {{No selflink|Drostanolone propionate}} || Oil solution || 100 mg 1–3x/week <noinclude> || <ref name="Lupulescu1990" /><ref name="Dao1975" /><ref name="Brotherton1976" /></noinclude>
|-
| {{No selflink|Metenolone enanthate}} || Oil solution || 400 mg 3x/week <noinclude> || <ref name="Brotherton1976" /></noinclude>
|-
| {{No selflink|Nandrolone decanoate}} || Oil solution || 50–100 mg 1x/1–3 weeks <noinclude> || <ref name="Deca-Durabolin-Label-AU">{{cite web | title = DECA-DURABOLIN (nandrolone decanoate) | publisher = | url = https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf| archive-url = https://web.archive.org/web/20190309024812/https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf| archive-date = 2019-03-09}}</ref><ref name="Deca-Durabolin-Label-NZ">{{cite web | title = DECA-DURABOLIN | work = New Zealand Data Sheet | url = http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf| archive-url = https://web.archive.org/web/20180128030754/http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf | archive-date = 2018-01-28 }}</ref><ref name="Shorr2007">{{cite book| vauthors = Shorr RI |title=Drugs for the Geriatric Patient E-Book|url=https://books.google.com/books?id=-gmjBQAAQBAJ&pg=PA844|date=11 April 2007|publisher=Elsevier Health Sciences|isbn=978-1-4377-1035-9|pages=844–}}</ref></noinclude>
|-
| {{No selflink|Nandrolone phenylpropionate}} || Oil solution || 50–100 mg/week <noinclude> || <ref name="McKone2013">{{cite book| vauthors = McKone WL |title=Osteopathic Athletic Health Care: Principles and practice|url=https://books.google.com/books?id=2bkACAAAQBAJ&pg=PA125|date=11 November 2013|publisher=Springer|isbn=978-1-4899-3067-5|pages=125–}}</ref><ref name="Brotherton1976" /></noinclude>
|- class="sortbottom"
| colspan="5" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Note:''' Dosages are not necessarily equivalent.<includeonly> '''Sources:''' See template.</includeonly>
|}<!--
--><noinclude>{{Documentation|content=
==See also==
* [[Template:Estrogen dosages for breast cancer]]
* [[Template:Estrogen dosages for prostate cancer]]
* [[Template:Androgen replacement therapy formulations and dosages used in women]]
* [[Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids]]
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>